We are on YouTube
Brittany L. Hayes, Ph.D. speaks at DCAT 2024 about Corden Pharma Highly Potent & Oncology Platform Highlights, focused on 3 main areas:
 
In the past year Corden Pharma launched their Drug Product Innovation Centre of Excellence at our CordenPharma Plankstadt (DE) facility, where they added bioavailability technologies like Hot Melt Extrusion (HME), spray drying, nanomilling and micronization. In addition, they have capabilities to take gram quantities of APIs to make small-scale prototypes for tablets or capsules, and using our Accelerated Stability Assessment Program, quickly identify and predict stability to bring your project rapidly into First-in-Human (FIH).
 
Secondly, they anticipate the opening of our new clinical trial area in Plankstadt, where they have the capacity to produce 5-60 Kilo batches of tablets and capsules using technologies such as wet and dry granulation, compression coating, and a state-of-the-art encapsulator with filling modules for direct API into individually weighed capsules, as well as powders, granules, pellets, and minitablets.
 
Lastly, in conjunction with their bioavailability enhancement technologies for non-GMP and long track record of experience with complex formulations, they are expanding into the oral solid dosage formulation of peptides. This exciting area provides oral ingestion of peptides via capsules or tablets, which offers definite advantages over traditional auto-injectors for your patients.

Brittany L. Hayes, Ph.D. speaks at DCAT 2024 about Corden Pharma Highly Potent & Oncology Platform Highlights, focused on 3 main areas:

In the past year Corden Pharma launched their Drug Product Innovation Centre of Excellence at our CordenPharma Plankstadt (DE) facility, where they added bioavailability technologies like Hot Melt Extrusion (HME), spray drying, nanomilling and micronization. In addition, they have capabilities to take gram quantities of APIs to make small-scale prototypes for tablets or capsules, and using our Accelerated Stability Assessment Program, quickly identify and predict stability to bring your project rapidly into First-in-Human (FIH).

Secondly, they anticipate the opening of our new clinical trial area in Plankstadt, where they have the capacity to produce 5-60 Kilo batches of tablets and capsules using technologies such as wet and dry granulation, compression coating, and a state-of-the-art encapsulator with filling modules for direct API into individually weighed capsules, as well as powders, granules, pellets, and minitablets.

Lastly, in conjunction with their bioavailability enhancement technologies for non-GMP and long track record of experience with complex formulations, they are expanding into the oral solid dosage formulation of peptides. This exciting area provides oral ingestion of peptides via capsules or tablets, which offers definite advantages over traditional auto-injectors for your patients.

0 0

YouTube Video VVVwVGY3NWZKWUsyMjlKNHFGZXRzMjVnLnhKbXhBb1RXdzlv

DCAT 2024 CORDEN PHARMA BRITTANY L HAYES

The Knowledge Hub TV

CPHI PHILADEPHIA 2024 Video Highlights

The Knowledge Hub TV

Latest news

This week’s featured articles

Life Sciences
Life Sciences
Life Sciences
Life Sciences
Life Sciences

Life Sciences Knowledge Hub

Stay up to date with industry news

Get the latest digital magazine and up to date news delivered right to your inbox.

Inside this issue
  • DCAT Week Preview
  • APIs
  • Biotech
  • CDMO
  • Women in Science

Spotlight on Life Sciences

Find out more


Partnered with top industry events and organisations